Recurrent AA Amyloidosis After Renal Transplantation
Mo kle
Abstrè
Deskripsyon
AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.
Dat
| Dènye verifye: | 03/31/2017 |
| Premye Soumèt: | 03/03/2016 |
| Enskripsyon Estimasyon Soumèt: | 03/03/2016 |
| Premye afiche: | 03/08/2016 |
| Dènye Mizajou Soumèt: | 04/14/2017 |
| Dènye Mizajou afiche: | 04/17/2017 |
| Dat aktyèl kòmanse etid la: | 01/31/2016 |
| Dat Estimasyon Prensipal Estimasyon an: | 09/30/2016 |
| Dat estime fini etid la: | 11/30/2016 |
Kondisyon oswa maladi
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| Recurrent AA amyloidosis Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft | |
| Control group 1 Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft | |
| Control group 2 Renal transplant recipients whose primary diseases are other than amyloidosis |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 18 Years Pou 18 Years |
| Sèks ki kalifye pou etid | All |
| Metòd echantiyonaj | Non-Probability Sample |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: - Renal transplantation recipients whose primary renal disease is AA amyloidosis; patients with allograft biopsy-confirmed AA amyloidosis (for study group) and patients with no clinical or laboratory signs of recurrence in the renal allograft (for control group 1) - Renal transplantation recipients whose primary diseases are other than AA amyloidosis (for control group 2) Exclusion Criteria: - Patients who are unwilling or unable to consent |
Rezilta
Mezi Rezilta Prensipal yo
1. Allograft survival [1 - 5 years]
Mezi Rezilta Segondè
1. Allograft rejection [1 - 5 years]
